1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 剤形別スニペット
3.2. 年齢層別スニペット
3.3. 用途別スニペット
3.4. 流通チャネル別スニペット
3.5. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. アレルギー疾患の増加
4.1.1.2. XX
4.1.2. 阻害要因
4.1.2.1. 薬剤に関連する副作用と副反応
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 剤形別
6.1. はじめに
6.1.1. 剤形別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数：剤形別
6.2. 錠剤
6.2.1. はじめに
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. ソリューション
6.4. シロップ
7. 年齢層別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）, 年齢層別
7.1.2. 市場魅力度指数（年齢層別
7.2. 年齢層別
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 成人
7.4. 小児
8. 用途別
8.1. 導入
8.1.1. 用途別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数、用途別
8.2. アレルギー性鼻炎
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. アレルギー性結膜炎
8.4. 慢性蕁麻疹
8.5. 湿疹
8.6. その他
9. 販売チャネル別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.1.2. 市場魅力度指数（流通チャネル別
9.2. 病院薬局
9.2.1. はじめに
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 小売薬局
9.4. オンライン薬局
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 主な地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析（%）、剤形別
10.2.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.2.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.2.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.2.7. 市場規模分析および前年比成長率分析（%）, 国別
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主な地域別ダイナミクス
10.3.3. 市場規模分析および前年比成長率分析（%）、剤形別
10.3.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.3.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.3.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.3.7. 市場規模分析および前年比成長率分析（%）, 国別
10.3.7.1. ドイツ
10.3.7.2. イギリス
10.3.7.3. フランス
10.3.7.4. スペイン
10.3.7.5. イタリア
10.3.7.6. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.3. 剤形別市場規模分析および前年比成長率分析（%） 10.4.4.
10.4.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.4.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.4.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.4.7. 市場規模分析および前年比成長率分析（%）, 国別
10.4.7.1. ブラジル
10.4.7.2. アルゼンチン
10.4.7.3. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.3. 剤形別市場規模分析および前年比成長率分析（%） 10.5.4.
10.5.4. 市場規模分析および前年比成長率分析（%）、年齢層別
10.5.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.5.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10.5.7. 市場規模分析および前年比成長率分析（%）, 国別
10.5.7.1. 中国
10.5.7.2. インド
10.5.7.3. 日本
10.5.7.4. 韓国
10.5.7.5. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 主な地域別ダイナミクス
10.6.3. 剤形別市場規模分析および前年比成長率分析（%） 10.6.4.
10.6.4. 市場規模分析および前年比成長率分析（%）：年齢層別
10.6.5. 市場規模分析および前年比成長率分析（%）, 用途別
10.6.6. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
11. 競争環境
11.1. 競争シナリオ
11.2. 市場ポジショニング／シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Johnson & Johnson Services, Inc.*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. GSK plc
12.3. UCB S.A.
12.4. Teva Pharmaceutical Industries Ltd.
12.5. Pfizer Inc.
12.6. Major Pharmaceuticals
12.7. Cipla
12.8. Dr. Reddys Laboratories Ltd.
12.9. AdvaCare Pharma
12.10. Aden Healthcare (*リストは除く)
13. 付録
13.1. アデンについて
13.2. お問い合わせ
The Global Cetirizine Hydrochloride Market reached US$ 6,797.9 million in 2023 and is expected to reach US$ 8,882.5 million by 2031 growing with a CAGR of 3.4% during the forecast period 2024-2031.
Cetirizine hydrochloride is a second-generation antihistamine that works by selectively blocking the action of histamine, a chemical released by the body during an allergic reaction. Histamine binds to H1 receptors on target cells, triggering a cascade of events that leads to the typical symptoms of allergies such as sneezing, itchy and watery eyes, runny nose, and hives.
By binding to the H1 receptors, cetirizine prevents histamine from exerting its effects, thereby alleviating allergy symptoms. Compared to first-generation antihistamines, cetirizine has a higher affinity for the H1 receptor and is less likely to cross the blood-brain barrier, resulting in fewer central nervous system side effects like drowsiness.
The broad applicability of cetirizine for various allergic conditions, along with its favorable safety profile, has made it a widely preferred option among healthcare providers for patients spanning all age groups, from young children to the elderly.
Market Dynamics: Drivers
Increasing prevalence of allergic diseases
The demand for the global cetirizine hydrochloride market is driven by multiple factors. One of the key factors is the increasing prevalence of allergic diseases. The rise in allergic conditions, such as allergic rhinitis, eczema, and allergic conjunctivitis, is a primary driver for the cetirizine market.
Currently, over 150 million Europeans suffer from chronic allergic diseases. This number is expected to rise, with predictions indicating that by 2025, more than 50% of the EU population could be affected by allergies, including conditions like allergic rhinitis, asthma, and eczema. There is a growing awareness among the public regarding allergies and the available treatment options, which is leading to an increased demand for cetirizine. As more individuals become familiar with the symptoms of allergies, they are more inclined to seek effective medications to alleviate their discomfort.
Moreover, key players in the industry more focus on research & development, and a rising number of clinical trials are helping to propel this market growth. For instance, in January 2024, UCB announced the randomized Phase III Study aims to assess the efficacy and safety of Xyzal (levocetirizine) compared to Zyrtec (cetirizine) in subjects suffering from dermatitis. This type of study is crucial in clinical research as it provides robust data on how well these medications perform in treating dermatitis, which is often characterized by inflammation, redness, and itching of the skin.
Restraints
Factors such as side effects & adverse reactions associated with the drugs, and stringent regulatory requirements, are expected to hamper the market.
Market Segment Analysis
The global cetirizine hydrochloride market is segmented based on dosage form, age group, application, distribution channels, and region.
The tablets segment accounted for approximately 64.3% of the global cetirizine hydrochloride market share
The tablets segment is expected to hold the largest market share over the forecast period. Cetirizine hydrochloride tablets are essential in the global market as a reliable treatment for various allergic conditions, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis. The increasing prevalence of allergies and growing awareness of effective allergy management strategies are anticipated to sustain the demand for cetirizine tablets over the forecast period.
In addition, key players in the industry strategies such as partnerships and collaborations are helping to propel this market growth. For instance, in August 2023, the National Medical Products Administration (NMPA) granted Xinhua Pharmaceutical (Gaomi) Co., Ltd., a wholly-owned subsidiary of Xinhua Pharmaceutical, the Approval Letter of Supplementary Application for Cetirizine Hydrochloride Tablets. This approval signifies that the product has successfully passed the quality and efficacy consistency evaluation required for generic drugs.
Market Geographical Share
North America accounted for approximately 43.9% of the global cetirizine hydrochloride market share
North America region is expected to hold the largest market share over the forecast period owing to the rise in allergic disorders, such as allergic rhinitis, chronic urticaria, and allergic conjunctivitis, which is a major factor propelling the demand for cetirizine hydrochloride in this region.
Allergic rhinitis, commonly known as hay fever, is a prevalent condition that affects a significant portion of the global population, with prevalence estimates ranging from 10% to 30%. In the United States, a substantial percentage of adults and children have reported experiencing seasonal allergies in recent years. According to data from the CDC, approximately 25.7% of U.S. adults and 18.9% of children stated they suffered from seasonal allergies in 2021.
This high prevalence of allergic rhinitis in the U.S. population creates a significant demand for antihistamine medications like cetirizine, which are effective in alleviating common symptoms associated with this condition, such as sneezing, runny nose, and itchy eyes. Moreover, growing public awareness of allergies and the treatment options accessible has led to a heightened demand for cetirizine.
Additionally, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and mergers & acquisitions are helping to propel this market growth in the region. For instance, in June 2022, Glenmark Pharmaceuticals Inc., USA, a fully owned subsidiary of Glenmark Pharmaceuticals Ltd., acquired the approved Abbreviated New Drug Applications (ANDAs) for several over-the-counter (OTC) drugs from Wockhardt Limited in the United States.
The acquired ANDAs include famotidine tablets USP, 10 mg and 20 mg (OTC) - used to treat and prevent ulcers in the stomach and intestine, cetirizine hydrochloride Tablets USP, 5 mg and 10 mg (OTC) - an antihistamine medication, and olopatadine hydrochloride ophthalmic solution USP, 0.1% (OTC) - indicated for allergic conjunctivitis and allergic rhinitis.
Market Segmentation
By Dosage Form
Tablets
Solutions
Syrups
By Age Group
Adult
Pediatric
By Applications
Allergic Rhinitis
Allergic Conjunctivitis
Chronic Urticaria
Eczema
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market
Competitive Landscape
The major global players in the cetirizine hydrochloride market include Johnson & Johnson Services, Inc., GSK plc, UCB S.A., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Major Pharmaceuticals, Cipla, Dr. Reddys Laboratories Ltd., AdvaCare Pharma, and Aden Healthcare among others.
Key Developments
In April 2023, Nicox SA announced that its exclusive partner in China, Ocumension Therapeutics, has submitted a New Drug Application (NDA) to obtain approval for the commercialization of Zerviate (cetirizine ophthalmic solution) at a concentration of 0.24%. This application is specifically for treating ocular itching associated with allergic conjunctivitis.
Why Purchase the Report?
To visualize the global cetirizine hydrochloride
Market Segmentation based on dosage form, age group, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the cetirizine hydrochloride market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global cetirizine hydrochloride market report would provide approximately 70 tables, 63 figures, and 183 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Dosage Form
3.2. Snippet by Age Group
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Allergic Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side Effects and Adverse Reactions Associated with the Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Dosage Form
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
6.1.2. Market Attractiveness Index, By Dosage Form
6.2. Tablet *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Solutions
6.4. Syrups
7. By Age Group
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Age Group*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Adult
7.4. Pediatric
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Allergic Rhinitis*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Allergic Conjunctivitis
8.4. Chronic Urticaria
8.5. Eczema
8.6. Others
9. By Distribution Channels
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Johnson & Johnson Services, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GSK plc
12.3. UCB S.A.
12.4. Teva Pharmaceutical Industries Ltd.
12.5. Pfizer Inc.
12.6. Major Pharmaceuticals
12.7. Cipla
12.8. Dr. Reddys Laboratories Ltd.
12.9. AdvaCare Pharma
12.10. Aden Healthcare (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us
❖ 世界のセチリジン塩酸塩市場に関するよくある質問(FAQ) ❖
・セチリジン塩酸塩の世界市場規模は？
→DataM Intelligence社は2023年のセチリジン塩酸塩の世界市場規模を67億9790万米ドルと推定しています。
・セチリジン塩酸塩の世界市場予測は？
→DataM Intelligence社は2031年のセチリジン塩酸塩の世界市場規模を88億8250万米ドルと予測しています。
・セチリジン塩酸塩市場の成長率は？
→DataM Intelligence社はセチリジン塩酸塩の世界市場が2024年～2031年に年平均3.4%成長すると予測しています。
・世界のセチリジン塩酸塩市場における主要企業は？
→DataM Intelligence社は「Johnson & Johnson Services, Inc.、GSK plc、UCB S.A.、Teva Pharmaceutical Industries Ltd.、Pfizer Inc.、Major Pharmaceuticals、Cipla、Dr. Reddys Laboratories Ltd.、AdvaCare Pharma、Aden Healthcareなど ...」をグローバルセチリジン塩酸塩市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
